Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 63 out of 100. Brain tissue and pathology

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

We examined the pattern of cognitive impairment and rate of cognitive and functional decline as a function of age at symptom onset in 127 patients with probable Alzheimer's disease (AD). At baseline, early-onset (before age 65) and late-onset groups were mildly and comparably impaired on the modified Mini-Mental State Examination (mMMS) and the Blessed Dementia Rating Scale-Part 1 (BDRS). Repeated-measures analysis of variance revealed significantly more rapid decline in early-onset subjects over a 2-year follow-up period.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 127 participants. Among 127 patients with probable Alzheimer's disease, those with symptom onset before age 65 declined more rapidly over two years than those with later onset, even though both groups were similarly impaired at the start. This means age at symptom onset may help predict how fast the disease progresses, but it does not point to a treatment or cure.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Jacobs, D., Sano, M., Marder, K., Bell, K., Bylsma, F., Lafleche, G., et al. (1994). Age at onset of Alzheimer's disease: relation to pattern of cognitive dysfunction and rate of decline. Neurology. https://doi.org/10.1212/wnl.44.7.1215

Vancouver

Jacobs D, Sano M, Marder K, Bell K, Bylsma F, Lafleche G, et al. Age at onset of Alzheimer's disease: relation to pattern of cognitive dysfunction and rate of decline. Neurology. 1994. doi:10.1212/wnl.44.7.1215. PMID: 8035918.

BibTeX

@article{jacobs1994-8035918,
  author  = {Jacobs, D. and Sano, M. and Marder, K. and Bell, K. and Bylsma, F. and Lafleche, G. and Albert, M. and Brandt, J. and others},
  title   = {{Age at onset of Alzheimer's disease: relation to pattern of cognitive dysfunction and rate of decline}},
  journal = {Neurology},
  year    = {1994},
  doi     = {10.1212/wnl.44.7.1215},
  pmid    = {8035918},
  url     = {https://doi.org/10.1212/wnl.44.7.1215}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

Among 127 patients with probable Alzheimer's disease, those with symptom onset before age 65 declined more rapidly over two years than those with later onset, even though both groups were similarly impaired at the start. This means age at symptom onset may help predict how fast the disease progresses, but it does not point to a treatment or cure.

Study details

How this study scored 63/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 2 of 6; Still being cited 2 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 63 of 100.63 of 100 points earned37 not earned

Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Neurology)
Journal's citation record 4 / 4 Neurology: journal h-index 525 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 1994 — older than 20 years, still counted
Sample size 2 / 4 127 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 268 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 7.9 citations a year over 34 year(s) since 1994
Impact for its field and year 3 / 6 Cited 3.2× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 6 other studies in this library
Still being cited 2 / 4 Cited 19 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Yaakov Stern: h-index 162 (OpenAlex, whole career)
Institution's track record 2 / 3 Johns Hopkins University: institution h-index 2,306 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 8035918)
Free to read 0 / 2 Behind a paywall — scores zero
Total 63 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Later studies that cite this one

6 studies in the alzhub library list this one in their references.

Related studies in Brain tissue and pathology from nearby years

Also in Brain tissue and pathology

124 studies in the library are filed under Brain tissue and pathology with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Brain tissue and pathology hub.

Similar studies

More on Brain tissue and pathology

See all studies in Brain tissue and pathology →